Quadrant Capital Group LLC raised its stake in shares of Shire PLC (NASDAQ:SHPG) by 157.6% during the second quarter, Holdings Channel reports. The fund owned 608 shares of the biopharmaceutical company’s stock after buying an additional 372 shares during the period. Quadrant Capital Group LLC’s holdings in Shire PLC were worth $101,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of SHPG. Sabal Trust CO acquired a new position in Shire PLC during the second quarter valued at $412,000. Huntington National Bank raised its position in Shire PLC by 1,578.3% in the second quarter. Huntington National Bank now owns 17,135 shares of the biopharmaceutical company’s stock valued at $3,154,000 after buying an additional 16,114 shares during the last quarter. Johnston Asset Management LLC raised its position in Shire PLC by 80.8% in the second quarter. Johnston Asset Management LLC now owns 131,109 shares of the biopharmaceutical company’s stock valued at $24,135,000 after buying an additional 58,607 shares during the last quarter. Northern Capital Management LLC raised its position in Shire PLC by 14.5% in the second quarter. Northern Capital Management LLC now owns 15,790 shares of the biopharmaceutical company’s stock valued at $2,907,000 after buying an additional 1,995 shares during the last quarter. Finally, Clean Yield Group acquired a new position in Shire PLC during the second quarter valued at $792,000. 24.26% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Shire PLC (NASDAQ:SHPG) traded up 1.51% during trading on Monday, hitting $197.44. The stock had a trading volume of 783,178 shares. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32. The stock has a market capitalization of $58.81 billion, a P/E ratio of 41.03 and a beta of 1.16. The stock’s 50-day moving average is $195.56 and its 200-day moving average is $187.04.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.35. The business had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. Shire PLC’s quarterly revenue was up 55.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.63 earnings per share. Analysts predict that Shire PLC will post $12.92 EPS for the current fiscal year.
The business also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were given a $0.139 dividend. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.
Several research firms recently weighed in on SHPG. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research report on Saturday. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Shire PLC in a research report on Monday, October 3rd. Leerink Swann reaffirmed a “buy” rating on shares of Shire PLC in a research report on Saturday, October 1st. Piper Jaffray Cos. set a $201.00 target price on Shire PLC and gave the stock a “hold” rating in a research report on Saturday, October 1st. Finally, Citigroup Inc. reaffirmed a “buy” rating on shares of Shire PLC in a research report on Tuesday, September 27th. Five equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. Shire PLC presently has a consensus rating of “Buy” and an average target price of $232.75.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.